Compare · DXCM vs MDT

DXCM vs MDT

Side-by-side comparison of DexCom Inc. (DXCM) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. DXCM focuses on Medical/Dental Instruments, while MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
  • MDT is the larger of the two at $129.97B, about 4.3x DXCM ($29.97B).
  • Over the past year, DXCM is up 34.8% and MDT is up 6.1% - DXCM leads by 28.8 points.
  • MDT has been more active in the news (16 items in the past 4 weeks vs 14 for DXCM).
  • Both have 25 recent analyst ratings on file.
PerformanceDXCM+34.83%MDT+6.07%
2025-11-12+0.00%2026-11-11
MetricDXCMMDT
Company
DexCom Inc.
Medtronic plc.
Price
-
-
Market cap
$29.97B
$129.97B
1M return
-5.54%
+9.32%
1Y return
+34.83%
+6.07%
Industry
Medical/Dental Instruments
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NASDAQ
NYSE
IPO
2005
News (4w)
14
16
Recent ratings
25
25
DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

MDT

Medtronic plc.

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Latest DXCM

Latest MDT